The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles

被引：0
作者：
Zahra Moayedfard
Farnaz Sani
Aliakbar Alizadeh
Kamran Bagheri Lankarani
Mohammad Zarei
Negar Azarpira
机构：
[1] Shiraz University of Medical Sciences,Department of Tissue Engineering and Cell Therapy, School of Advanced Technologies in Medicine
[2] Tarbiat Modares University,Hematology and Cell Therapy Department, Faculty of Medical Sciences
[3] Shiraz University of Medical Sciences,Health Policy Research Center (HPRC)
[4] Harvard Medical School,Renal Division, Brigham and Woman’s Hospital
[5] Harvard T.H. Chan School of Public Health,John B. Little Center for Radiation Sciences
[6] Shiraz University of Medical Sciences,Transplant Research Center
来源：
Stem Cell Research & Therapy | / 13卷
关键词：
Mesenchymal stem cells; Extracellular vesicle; Liver disease; miRNA; NAFLD; Immune response; Inflammation; Exosomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by intra-hepatocyte triglyceride accumulation and concomitant involvement of the immune system with subsequent histological changes, tissue damage, and clinical findings. There are various molecular pathways involved in the progression of NAFLD including lipotoxicity, endoplasmic reticulum stress, and the immune response. Both innate and adaptive immune systems are involved in the NAFLD pathogenesis, and crosstalk between the immune cells and liver cells participates in its initiation and progression. Among the various treatments for this disease, new cell based therapies have been proposed. Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSC) (MSC-EVs) are new cell-free vehicles with low immunogenicity, which can suppress detrimental immune responses in inflamed tissues. This review aimed to express the immune system’s molecular pathways associated with the initiation and progression of NAFLD. Then, the possible role of MSC-EVs in the treatment of this entity through immune response modulation was discussed. Finally, engineered EVs enhanced by specific therapeutic miRNA were suggested for alleviating the pathological cellular events in liver disease.
引用
收藏
相关论文
共 619 条
  • [1] Smith BW(2011)Non-alcoholic fatty liver disease Crit Rev Clin Lab Sci 48 97-113
  • [2] Adams LA(2016)Adipose tissue, obesity and non-alcoholic fatty liver disease Minerva Endocrinol 42 92-108
  • [3] Polyzos SA(2013)Characteristics and diagnosis of NAFLD/NASH J Gastroenterol Hepatol 28 64-70
  • [4] Kountouras J(2012)The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 1592-1609
  • [5] Mantzoros CS(2002)Non-alcoholic steatohepatitis: Definitions and pathogenesis J Gastroenterol Hepatol 17 S377-S384
  • [6] Hashimoto E(2010)Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites Hepatology 52 774-788
  • [7] Taniai M(2010)Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 52 1836-1846
  • [8] Tokushige K(2014)Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome Lancet Diabetes Endocrinol 2 901-910
  • [9] Chalasani N(2019)Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis Cells 8 727-1653
  • [10] Younossi Z(2013)The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles Proteomics 13 1637-e13
12345678910